Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

IOLITE is an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 study with a crossover design to evaluate KB803, administered as an eye drop, for the treatment and prevention of ...

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic ...

KB803 is a redosable, eye drop gene therapy designed to deliver two copies of the COL7A1 transgene to the epithelial cells in a patient's eye for the treatment and prevention of corneal abrasions ...

PITTSBURGH, June 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 3 clinical trial (“IOLITE”), an ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

"I congratulate the government and people of Burundi and commend them for their hard work and dedication. The elimination of ...

Doctors describe some of the most common injuries caused by fireworks — and how to prevent them without missing out on the ...

Sports-related orbital fractures remain a significant contributor to facial trauma, especially among young males, according to a retrospective cohort study. Using a national injury database, a total ...

It's not only caused by needing corrective lenses. Leading eye doctors share which conditions—big and small—can cause blurry ...

KeraLink International, a nonprofit organization dedicated to eradicating corneal blindness globally, has an ambitious goal: ...

Corneal Endothelial Dystrophy Pipeline constitutes 4+ key companies continuously working towards developing 4+ Corneal Endothelial Dystrophy treatment therapies, analyzes DelveInsight.